Key result
Outpatient treatment of VTE with apixaban was associated with significantly lower risks of major bleeding (HR 0.75; 95% CI 0.64-0.87) and recurrent VTE (HR 0.80; 95% CI 0.70-0.91) versus warfarin.
Why the study?
Does apixaban reduce bleeding and recurrent VTE compared to warfarin in patients with acute VTE treated as outpatients?
Cohort (n=35,756)
Yes
Does apixaban reduce bleeding and recurrent VTE compared to warfarin in patients with acute VTE treated as outpatients?
Hazard Ratio: 0.75 (95% CI 0.64–0.87)
Absolute Event Rate: 1.7% vs 2.3%
In routine U.S. clinical practice, outpatient treatment of VTE with apixaban is associated with significantly lower risks of recurrent VTE and bleeding compared to warfarin.
No takes yet. Share an insight, caveat, or question.
May support apixaban preference for outpatient VTE; hypothesis-generating and leaves randomized confirmation open.
Weycker et al. (2018) conducted a cohort in Acute venous thromboembolism (VTE) (n=35,756). Apixaban vs. Warfarin plus parenteral anticoagulant bridge therapy was evaluated on Major bleeding (HR 0.75, 95% CI 0.64-0.87). Outpatient treatment of VTE with apixaban was associated with significantly lower risks of major bleeding (HR 0.75; 95% CI 0.64-0.87) and recurrent VTE (HR 0.80; 95% CI 0.70-0.91) versus warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: